S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
VANCOUVER & DALLAS - Alpha Cognition Inc. (NASDAQ:ACOG) announced Tuesday that its drug candidate ALPHA-1062 showed promising results in preclinical studies for treating mild traumatic brain injury (mTBI), particularly those resulting from repetitive blast trauma in military settings.
The study, supported by the US Department of Defense and conducted with the US Department of Veterans Affairs and the Seattle Institute of Biomedical and Clinical Research, demonstrated that ALPHA-1062 administration following blast-induced mTBI reduced several markers of brain injury.
According to the company, the drug reduced brain levels of three toxic forms of the Tau protein, including pTau 217, which has been suggested to identify TBI patients at greater risk of long-term cognitive decline. The drug also decreased neuroinflammation markers and increased nerve growth factor receptor expression, which plays a role in neuronal survival.
"These outcomes are in agreement with those of an earlier pre-clinical study in a moderate TBI animal model, both studies demonstrated protective effects of ALPHA-1062," said Denis Kay, Alpha Cognition’s Chief Scientific Officer, in the press release.
The company plans to complete formulation of ALPHA-1062 for sublingual administration and conduct a bridging pharmacokinetic study comparing it to ZUNVEYL (Benzgalantamine) and an existing intranasal formulation.
Alpha Cognition recently received FDA approval for ZUNVEYL, a delayed release oral tablet formulation of ALPHA-1062, for the treatment of Alzheimer’s disease. The company describes it as a new generation acetylcholinesterase inhibitor with expected minimal gastrointestinal side effects. InvestingPro data shows the company maintains strong financial flexibility with a current ratio of 17.14, indicating robust short-term liquidity to support its drug development programs.
Service-related mTBI often results in persistent physical and emotional challenges for patients and increases the risk of dementia diagnosis later in life, according to the company’s statement. The stock has shown strong momentum with a 58.4% return over the past six months, though InvestingPro subscribers have access to 8 additional key insights about the company’s financial health and growth prospects.
In other recent news, Alpha Cognition Inc. announced significant changes to its board of directors. John Havens, a current board member, has opted not to seek re-election at the upcoming annual stockholders’ meeting. His decision was stated to be unrelated to any disagreements with the company’s operations or policies. Concurrently, Alpha Cognition has appointed Robert Wills, Ph.D., to its board and the Governance and Nominating Committee. Dr. Wills brings extensive experience from his previous roles at Johnson & Johnson and other organizations in the pharmaceutical and biotechnology sectors. As part of his compensation, Dr. Wills will receive an annual salary of $40,000, an additional $5,000 for committee service, and 35,575 stock options with an exercise price of $4.83 per share. These options will vest over 24 months. The company confirmed that there are no other arrangements or family ties between Dr. Wills and other executives or directors. Additionally, Dr. Wills holds no material interests in transactions requiring disclosure under SEC regulations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.